Search results
Results from the WOW.Com Content Network
Several approved drugs are being investigated as repurposed agents in the treatment of osteoarthritis such as liraglutide (anti-diabetic and anti-obesity drug: NCT02905864), Metformin (anti-diabetic drug: NCT04767841, NCT05034029), Zoledronic acid (anti-osteoporotic drug: NCT04303026), etc. [4] Paroxetine has been deemed to have dmoad activity ...
1.09 Alkylating agents: Altretamine: PO Alkylates DNA. Recurrent or advanced ovarian cancer Myelosuppression, peripheral neuropathy, seizures and hepatotoxicity (rare). Bendamustine: IV: Alkylates DNA. Chronic lymphocytic leukaemia, mantle cell lymphoma and non-Hodgkin's lymphoma. Myelosuppression, hypokalaemia and tachycardia. Busulfan: IV, PO ...
ATC code M05 Drugs for treatment of bone diseases is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
[citation needed] More recently, the term has been used to indicate a drug that reduces the rate of damage to bone and cartilage. [ citation needed ] DMARDs can be further subdivided into traditional small molecular mass drugs synthesised chemically and newer "biological" agents produced through genetic engineering.
Biological response modifiers (BRMs) are substances that modify immune responses.They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs), and they can either enhance an immune response or suppress it.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
There was plenty of domination in 2024. The Chiefs positioned themselves for an unprecedented three-peat. UConn went back-to-back. Caitlin Clark could hardly be stopped on or off the court.
Pharmaceutical agents that will alter the natural history of disease progression by arresting joint structural change and ameliorating symptoms are termed as disease modifying therapy. [63] Therapies under investigation include the following: Strontium ranelate – may decrease degeneration in osteoarthritis and improve outcomes [202] [203]